Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

849
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
849
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

974
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
974
Glaucoma: Overview01:25

Glaucoma: Overview

1.1K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.1K
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

8.1K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Looking at Optic Nerve Sheath Meningiomas Through Genetics-From Clinic to Bench and Back Again.

Frontiers in bioscience (Scholar edition)·2026
Same author

Archetypal Visual Field Analysis of Patients With Chronic Leber Hereditary Optic Neuropathy in Relation to Visual Recovery.

Investigative ophthalmology & visual science·2026
Same author

Sustained attention in dementia with Lewy bodies: a task-based fMRI study.

Frontiers in aging neuroscience·2026
Same author

Expanding the landscape of tRNA pathogenic variants in mitochondrial DNA.

Brain communications·2026
Same author

Functional Classification of a New IOL Into the Category of Partial Depth of Field: Enhanced IOLs According to the ESCRS Criteria.

Journal of refractive surgery (Thorofare, N.J. : 1995)·2026
Same author

Effect of IOP-lowering treatment and Pentoxifylline on retrobulbar blood flow in normal tension glaucoma: a color doppler imaging study.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026

Related Experiment Video

Updated: Dec 1, 2025

Minimally-invasive Technique for Injection into Rat Optic Nerve
07:34

Minimally-invasive Technique for Injection into Rat Optic Nerve

Published on: May 19, 2015

10.0K

Therapeutic Options in Hereditary Optic Neuropathies.

Giulia Amore1, Martina Romagnoli2, Michele Carbonelli2

  • 1Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy.

Drugs
|November 7, 2020
PubMed
Summary

Effective treatments for hereditary optic neuropathies are emerging. While idebenone offers an option for Leber

More Related Videos

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
08:17

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo

Published on: September 22, 2017

19.8K
A Surgical Approach for Optic Nerve Crush in a Rabbit Model
06:15

A Surgical Approach for Optic Nerve Crush in a Rabbit Model

Published on: July 8, 2025

966

Related Experiment Videos

Last Updated: Dec 1, 2025

Minimally-invasive Technique for Injection into Rat Optic Nerve
07:34

Minimally-invasive Technique for Injection into Rat Optic Nerve

Published on: May 19, 2015

10.0K
Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
08:17

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo

Published on: September 22, 2017

19.8K
A Surgical Approach for Optic Nerve Crush in a Rabbit Model
06:15

A Surgical Approach for Optic Nerve Crush in a Rabbit Model

Published on: July 8, 2025

966

Area of Science:

  • Ophthalmology and Genetics
  • Neuroscience
  • Pharmacology

Background:

  • Hereditary optic neuropathies, including Leber's Hereditary Optic Neuropathy (LHON) and dominant optic atrophy (DOA), represent significant challenges in visual health.
  • Current treatment options are limited, with idebenone being a notable advancement for LHON, but a broader therapeutic landscape is required for various mitochondrial optic neuropathies.
  • The development of novel therapeutic strategies targeting diverse molecular pathways is crucial for addressing these debilitating conditions.

Purpose of the Study:

  • To provide a comprehensive review of current and emerging treatment options for hereditary optic neuropathies.
  • To analyze proposed molecular targets, preclinical evidence, and clinical trial outcomes for various therapeutic agents.
  • To outline future therapeutic scenarios, including gene therapy, gene editing, and reproductive strategies for mitochondrial DNA mutations.

Main Methods:

  • Systematic review of scientific literature focusing on hereditary optic neuropathies.
  • Analysis of preclinical data and clinical trial results for pharmaceutical agents and gene therapies.
  • Evaluation of molecular mechanisms, including antioxidant effects, anti-apoptotic actions, and mitobiogenesis activation.

Main Results:

  • Idebenone has been successfully introduced for Leber's Hereditary Optic Neuropathy (LHON).
  • Multiple agents targeting different pathways are in Phase II or preclinical development for various mitochondrial optic neuropathies.
  • Gene therapy has reached Phase III for LHON and is being explored for dominant optic atrophy (DOA).

Conclusions:

  • The therapeutic landscape for hereditary optic neuropathies is expanding with promising agents and advanced gene therapies.
  • Future strategies may include gene editing and reproductive options to prevent the transmission of mitochondrial DNA mutations.
  • Continued research and clinical trials are essential to bring effective treatments to patients with these conditions.